United States

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

29 Mar 2017
Change (% chg)

$-0.02 (-0.80%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Wed, Mar 15 2017

BRIEF-Idera Pharmaceuticals reports Q4 earnings per share $0.01

* Idera Pharmaceuticals reports fourth quarter and year end 2016 financial results and provides corporate update

BRIEF-Idera Pharma reports positive Phase 1 data for IMO-2125

* Idera Pharmaceuticals presents update from ongoing phase 1 dose escalation clinical trial of Intratumoral IMO-2125 in combination with Ipilimumab in metastatic melanoma patients refractory to Anti-PD-1 treatment at the 2017 ASCO-SITC clinical Immuno-Oncology Symposium

BRIEF-Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd enter into license agreement

* Press release - Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter into exclusive license agreement for the worldwide rights to IMO-9200

BRIEF-Idera reports data from ongoing Phase 1 clinical trial of intratumoral IMO-2125

* Idera Pharmaceuticals reports translational data supporting the mechanism of action of intratumoral IMO-2125 from ongoing Phase 1 dose escalation in clinical trial in combination with ipilimumab in metastatic melanoma patients refractory to anti-pd-1 trea Source text for Eikon: Further company coverage:

BRIEF-Idera Pharmaceuticals Q3 loss per share $0.10

* Idera Pharmaceuticals reports third quarter 2016 financial results

BRIEF-Baker Bros. Advisors LP reports 7.2 pct stake in Idera Pharmaceuticals - SEC filing

* Baker Bros. Advisors LP reports 7.2 percent stake in Idera Pharmaceuticals Inc as of Oct. 7 - sec filing Source text (http://bit.ly/2dOyHXg) Further company coverage:

BRIEF-Idera Pharma says announces proposed public offering of common stock

* Idera pharmaceuticals inc says intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering

Select another date:

More From Around the Web